OrthoPediatrics' Free-Cash-Flow Turning Point Arrives With Its First $70 Million Quarter

Every medical-device growth story eventually has to answer one question: does revenue turn into cash? For OrthoPediatrics (NASDAQ: KIDS), the pediatric-orthopedics specialist, that question has hung over the stock for years. Its model is unlike most device makers: it ships expensive sets of surgical instruments into hospitals as capital, then bills for the cases those instruments enable over years. That up-front spending is exactly why the income statement stayed red while revenue compounded. The market priced KIDS as a capable but unprofitable niche player condemned to keep burning cash in order to grow.

The second quarter changes the shape of that story. Revenue was $70.5 million, the first quarter above $70 million in company history and up 15% from a year earlier. And free cash flow use fell to $3.1 million from $13.9 million a year ago, a 78% improvement. The company still reported a net loss of $0.30 a share, but the cash-flow picture is what matters, and it moved sharply in the right direction.

The cash that never showed up

The reason KIDS spent years reporting red cash flow is the "set" model. The company deploys roughly $10 million a year of instrument sets as capital. A set is a tray of specialized tools — cannulated screws, plates, rods — that sits inside a hospital or ambulatory surgery center, ready for a pediatric procedure. OrthoPediatrics does not simply sell a product; it pre-positions hospital equipment and then collects a stream of case revenue as surgeons use it. That is a heavy, front-loaded investment: the faster it grows, the more sets it must place before it earns the recurring revenue on them.

That structure is also why the inflection matters. As the installed base of sets matures, the incremental revenue on sets already deployed needs no new capital, so a larger share of each new dollar flows to cash. The quarter shows that mechanism starting to work — revenue up 15%, free cash flow use down 78%. Growth is finally doing what it should and converting to the bottom line.

Where the quarter changed

The growth is concentrated where the model works best. Trauma and Deformity, the core franchise, rose 26% to $52.6 million, and international revenue rose 22%. The soft spot is Scoliosis, down 9%, which management tied to timing on capital placements and international distributor set sales, partially offset by growth in its Response fusion line. A one-quarter dip in a segment that historically took share is worth watching, but it is not yet proof the path broke.

Management raised full-year guidance again during the quarter — revenue now $265 million to $269 million, representing 12% to 14% growth, with adjusted EBITDA of about $25 million, record profitability for the company. It also reiterated that it expects to reach breakeven free cash flow in 2026. Breakeven would be a first, and it is the reset the market has been waiting on.

The honest price

Let me be direct about the uncomfortable part. This is not a cheap stock the moment you open the tape. The market cap is about $563 million, enterprise value near $617 million, and the company still loses money on a GAAP basis. You cannot compute a tidy forward free-cash-flow multiple today because 2026 is roughly breakeven — the rerating bet is on 2027, not 2026: that breakeven turns positive next year as the mature set base keeps converting growth into cash.

The headlines can say whatever they want. The market is still pricing the old risk profile while the operating setup is already getting cleaner. The stock sits near $21.50, up about 30% over four months and down roughly 5% over the past week — it has bounced hard off its 52-week low of $14.42, but it has not yet re-rated to the point where anyone believes the cash conversion is real. This is not about excitement. It is about a business that may soon become far harder to dismiss once the free cash flow shows up. I can be wrong again, and the price is what it is. But the setup is a genuine expectations reset.

What would break it

The bear case is not exotic — it is a balance sheet and a timing question. The company carries net debt of roughly $54 million, and cash and investments fell from $62.9 million at year-end 2025 to $47.9 million by June 30. If the free cash flow improvement is partly timing, a quiet quarter on set purchases rather than durable operating leverage, the cash drain picks right back up. And if the Scoliosis dip is actually share loss to the larger orthopedics players rather than timing, the growth mix gets worse.

So the specific condition to watch is narrow. Keep set capital near that $10 million a year while revenue keeps growing, and free cash flow crosses into positive territory in 2027 after breakeven this year. If instead the cash keeps falling and capital spending has to re-accelerate to support growth, that is the sign the story is still the old one. If the cash shows up, this is a business that grows double digits and finally keeps what it earns — and that is a very different valuation argument than the market has been making.